AdvancedMD Becomes an Independent Company Following Acquisition by Marlin Equity Partners

South Jordan, UT – Sept 2, 2015 – AdvancedMD, the pioneer in cloud technology for physician practices, today announced that it began operations as a standalone company following the completion of its sale to Marlin Equity Partners, a global investment firm with over $3 billion of capital under management. Now known simply as AdvancedMD, the company continues to deliver fully-integrated electronic health records, practice management and patient relationship management software solutions, as well as big data reporting and business intelligence tools, designed to automate and optimize workflow in all areas of physician practices. AdvancedMD also today reiterated its commitment to independent physicians and launched new branding to reflect this commitment and its own independence.

AdvancedMD is one of the most comprehensive technology ecosystems designed for private practices and serves an expansive national footprint of more than 17,500 practitioners and 500 medical billing companies. The new AdvancedMD tagline, ‘Freedom to Practice,’ is derived from their focus on alleviating compliance challenges, streamlining workflow and ensuring providers get paid using state of the art medical billing power tools.

Raul Villar, formerly ADP AdvancedMD president, will continue as CEO of the independent company after a 26-year career with ADP. “As the largest provider of clinical and financial solutions to independent medical practices, AdvancedMD is dedicated to providing crucial solutions and resources that enable our customers to grow and succeed. We are excited to continue our mission and unveil branding that reflects our new status and strengthened conviction as a standalone company. With Marlin’s financial and operational support, we have the ability to continue to deliver unmatched value to our clients and partners.”

“We are thrilled to partner with the team at AdvancedMD to support the next chapter of the company’s growth,” said Michael Anderson, a principal at Marlin. “AdvancedMD is led by a strong management team with a clear vision for how technology can improve the productivity and care that independent physicians can provide to their patients. We are highly confident we can help accelerate the company’s impressive growth and build upon the valuable customer relationships that have allowed the business to reach this point.”

About Marlin Equity Partners
Marlin Equity Partners is a global investment firm with over $3 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries where its capital base, industry relationships and extensive network of operational resources significantly strengthens a company’s outlook and enhances value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 90 acquisitions. The firm is headquartered in Los Angeles, California with an additional office in London. For more information, please visit www.marlinequity.com.

About AdvancedMD
AdvancedMD is a leading provider of cloud-based practice management (PM), electronic health records (EHR) and revenue cycle management (RCM) solutions focused on the independent physician practice market. The company’s comprehensive portfolio allows physicians to drive additional revenue and reduce administrative burden by automating medical practice processes, optimizing patient schedules and encounters, streamlining insurance claim creation, managing prescription and order processes, and by tracking and analyzing financial performance. AdvancedMD is widely recognized as a leader in its industry, and has earned the #1 ranking from KLAS, the leading independent industry analyst, in a number of categories including product quality, functionality and integration. For more information, please visit www.advancedmd.com.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.